25dkou351 10.3205/25dkou351 urn:nbn:de:0183-25dkou3511 Meeting Abstract Elias Elias Daniel D

Luzerner Kantonsspital, Klinik für Orthopädie und Unfallchirurgie, Luzern, Schweiz Universität Luzern, Fakultät für Gesundheitswissenschaften und Medizin, Luzern, Schweiz

author Van de Wall Van de Wall Bryan B

Luzerner Kantonsspital, Klinik für Orthopädie und Unfallchirurgie, Luzern, Schweiz Universität Luzern, Fakultät für Gesundheitswissenschaften und Medizin, Luzern, Schweiz

author Bucher Bucher Jörg J

Luzerner Kantonsspital, Klinik für Orthopädie und Unfallchirurgie, Wolhusen, Schweiz

author Link Link Björn-Christian BC

Luzerner Kantonsspital, Klinik für Orthopädie und Unfallchirurgie, Luzern, Schweiz Universität Luzern, Fakultät für Gesundheitswissenschaften und Medizin, Luzern, Schweiz

author Haefeli Haefeli Pascal P

Luzerner Kantonsspital, Klinik für Orthopädie und Unfallchirurgie, Luzern, Schweiz Universität Luzern, Fakultät für Gesundheitswissenschaften und Medizin, Luzern, Schweiz

author German Medical Science GMS Publishing House

Düsseldorf

610 20251031 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0634 351 Deutsche Gesellschaft für Orthopädie und Unfallchirurgie Deutsche Gesellschaft für Orthopädie und Orthopädische Chirurgie Deutsche Gesellschaft für Unfallchirurgie Berufsverband für Orthopädie und Unfallchirurgie Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2025) Abstracts | Primär- und Revisionsendoprothetik – Operationstechnik Berlin 20251028 20251031 AB53-4332 TextObjectives and questions: Mixing implant components from different manufacturers in primary total hip arthroplasty (THA) is considered when the matching counterpart of a preferred component from the same manufacturer does not meet the patient's specific requirements or has shown inferior results compared to a compatible component from another manufacturer. However, this practice remains controversial due to liability concerns and uncertainty regarding its impact on revision rates. This meta-analysis compares brand-mixed and brand-unmixed primary THA concerning revision rates, complications, and functional outcomes.Material and methods: A comprehensive search was conducted on PubMed, Medline, and Embase for randomized clinical trials (RCTs) and observational studies. Effect estimates were systematically pooled across studies using random-effects models and presented as weighted odds ratios (ORs) with their corresponding 95% confidence intervals (95% CIs).Results: Four studies were included in the analysis with 128,548 patients (17.7%) receiving a brand-mixed THA and 596,986 patients (82.3%) receiving a brand-unmixed THA. The overall revision rate was comparable in both groups (2.3% for brand-mixed vs. 2.5% for brand-unmixed, OR 0.98, 95% CI 0.78–1.24). Furthermore, following the exclusion of components exhibiting substandard performance, such as metal-on-metal bearings and other combinations previously identified as contributing to elevated revision rates in both brand-mixed and brand-unmixed groups, no statistically significant difference was observed between the two groups (2.04% for brand-mixed vs. 1.95% for brand-unmixed, OR 1.03, 95% CI 0.84–1.26). Two studies reported on the reasons for revision. The most prevalent indication for revision in both treatment groups was due to dislocation (32% for brand-mixed vs. 29% for brand-unmixed). Other complications, including loosening of the femoral and acetabular component, periprosthetic fracture, cup/liner wear, and septic revision were comparable across the treatment groups. One study reported on functional outcomes and revealed no significant disparities in Oxford Hip Scores at the six-month follow-up.Discussion and conclusions: The present meta-analysis demonstrates no significant difference in revision rates, complications, and functional outcomes between brand-mixed and brand-unmixed primary total hip arthroplasty. Scientifically, the evidence suggests that orthopedic surgeons should not hesitate to use compatible components from different manufacturers when clinically appropriate. 0 0 0 0